Drug Profile
Research programme: cancer therapies - H3 Biomedicine
Alternative Names: SF3B1 inhibitors - H3 Biomedicine; SF3B1 modulator - H3 Biomedicine; Splicing factor inhibitor - H3 Biomedicine; Splicing inhibitors - H3 BiomedicineLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator H3 Biomedicine
- Developer H3 Biomedicine; University of British Columbia; Vancouver Coastal Health
- Class Antineoplastics
- Mechanism of Action Estrogen receptor antagonists; Phosphoprotein modulators; RNA interference; Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
- 28 May 2019 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 08 Jan 2018 H3 Biomedicine announces intention to submit IND application for Cancer in 2019